Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies.
Fracasso PM, Goldstein LJ, de Alwis DP, Rader JS, Arquette MA, Goodner SA, Wright LP, Fears CL, Gazak RJ, Andre VA, Burgess MF, Slapak CA, Schellens JH.
Fracasso PM, et al. Among authors: goldstein lj.
Clin Cancer Res. 2004 Nov 1;10(21):7220-8. doi: 10.1158/1078-0432.CCR-04-0452.
Clin Cancer Res. 2004.
PMID: 15534095
Clinical Trial.